Login to Your Account



Eddingpharm expands portfolio with ACT Biotech assets


Wednesday, January 15, 2014

HONG KONG – Among the fastest-growing specialty pharmaceutical companies in China, Eddingpharm Inc. has made a move to consolidate domestic and international oncology drug development through a deal that could be worth as much as $95 million.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription